VIVORYON THERAPEUTICS NV (VVY.AS) Stock Earnings & Estimates
Europe - AMS:VVY - NL00150002Q7 - Common Stock
1.674 EUR
-0.01 (-0.36%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 10.764M | -100.00% | -3.62M | 100.00% | 1.43B | 1.748B 22.24% | |||||
| EBITDA YoY % growth | -12.633M 20.37% | -28.952M -129.18% | -28.67M 0.97% | -21.516M 27.40% | -14.127M 32.13% | -16.103M -13.99% | -17.645M -9.58% | N/A | N/A | N/A | |
| EBIT YoY % growth | -12.798M 20.07% | -29.113M -127.48% | -28.837M 0.95% | -23.132M 27.31% | -11.974M 42.88% | -15.296M -27.75% | -15.998M -4.59% | -23.7M -48.14% | 1.404B 6,024.13% | 1.721B 22.58% | |
| Operating Margin | -118.90% | N/A | 796.60% | N/A | N/A | N/A | N/A | N/A | 98.18% | 98.46% | |
| EPS YoY % growth | -0.63 24.10% | -1.28 -103.17% | -1.12 12.50% | -0.94 29.46% | -0.44 44.39% | -0.58 -32.18% | -0.62 -6.96% | -1.07 -71.87% | 40.77 3,919.15% | 50.00 22.62% |
All data in EUR
| Q4 / 25 | Q2 / 26 | Q4 / 26 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.21 21.44% | -0.30 -44.29% | -0.39 -85.71% |
| Revenue Q2Q % growth | N/A | N/A | N/A |
| EBITDA Q2Q % growth | -5.474M 21.89% | N/A | N/A |
| EBIT Q2Q % growth | -5.555M 22.36% | N/A | N/A |
All data in EUR
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.21 59.62% | -0.22 | 0.01 | 5.49% |
| Q4 2024 Q2Q % growth | -0.27 60.29% | -0.29 | 0.02 | 7.82% |
| Q2 2024 Q2Q % growth | -0.52 -18.18% | -0.62 | 0.10 | 16.28% |
| Q4 2023 Q2Q % growth | -0.68 | -0.58 | -0.10 | -17.09% |
| Q2 2023 Q2Q % growth | -0.44 26.67% | -0.61 | 0.17 | 27.39% |
| Q4 2022 Q2Q % growth | -0.68 -1,260.00% | -0.61 | -0.07 | -12.21% |
| Q2 2022 Q2Q % growth | -0.60 -3.45% | -0.63 | 0.03 | 4.18% |
| Q4 2021 Q2Q % growth | -0.05 88.89% | -0.41 | 0.36 | 87.93% |
| Q2 2021 Q2Q % growth | -0.58 -52.63% | -0.59 | 0.01 | 0.99% |
| Q4 2020 Q2Q % growth | -0.45 21.05% | -0.42 | -0.03 | -6.08% |
| Q2 2020 Q2Q % growth | -0.38 -25.02% | -0.16 | -0.22 | -135.15% |
| Q4 2019 Q2Q % growth | -0.57 | -0.39 | -0.18 | -44.71% |
| Q2 2019 Q2Q % growth | -0.30 | -0.25 | -0.05 | -20.37% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2024 Q2Q % growth | 100.00% | % | ||
| Q4 2022 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | 37.86% | 37.86% |
| Revenue | N/A | N/A | N/A | N/A |